{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:39Z","timestamp":1792782639687,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University","id":[{"id":"https:\/\/ror.org\/05kb8h459","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The benefits of neoadjuvant therapy (NAT) for pancreatic cancer (PC) with portal venous involvement remain debated. This study aimed to compare the short- and long-term outcomes of surgery with or without NAT in patients with PC with suspected venous involvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre retrospective cohort study compared patients who underwent upfront surgery (US) or surgery following NAT for PC with suspicion of venous involvement between 2007 and 2017. The primary endpoints were short-term morbidity and mortality, overall survival and disease-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 361 patients who received NAT and 690 patients who underwent US at nine centres. NAT patients had greater suspicion of venous involvement (96.9% vs. 83.6%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), but underwent fewer venous resections (53.7% vs. 79.3%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), and had less venous infiltration (52.3% vs 65.9%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), perineural invasion (75.2% vs. 90.1%, p&lt;0.001), angioinvasion (59.9% vs. 76.7%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), lymph node involvement (60.6% vs. 83.6%, p&lt;0.001) and R1 resections (44.7% vs. 67.2%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001) than patients who underwent US. Among patients undergoing venous resection, major postoperative complications were similar between the groups. However, without venous resection, NAT patients had significantly fewer (Clavien-Dindo \u2265IIIb) postoperative complications (10.8% vs. 24.4%,\n                      <jats:italic>p<\/jats:italic>\n                      =0.02), fewer reoperations (3.0% vs. 11.2%,\n                      <jats:italic>p<\/jats:italic>\n                      =0.006), and lower 90-day mortality (2.4% vs. 7.7%,\n                      <jats:italic>p<\/jats:italic>\n                      =0.03). NAT patients showed improved survival (27.3 vs. 21.2 months,\n                      <jats:italic>p<\/jats:italic>\n                      =0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NAT maybe beneficial for patients with PC with venous involvement, as it might allow better patient selection for surgery and is associated with fewer major postoperative complications and better overall survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00423-026-04291-0","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:54:44Z","timestamp":1790056484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis"],"prefix":"10.1007","volume":"411","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0343-8978","authenticated-orcid":false,"given":"Asif","family":"Halimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline S.","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengi S.","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benediktas","family":"Kurlinkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reea","family":"Ahola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Del Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Sparrelid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rangelova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Maggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Malleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Lionetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giovinazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Belfiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Laukkarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcralp O.","family":"Ceyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"19","key":"4291_CR1","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825","journal-title":"N Engl J Med"},{"issue":"8","key":"4291_CR2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","volume":"48","author":"CG Moertel","year":"1981","unstructured":"Moertel CG, Frytak S, Hahn RG, O\u2019Connell MJ, Reitemeier RJ, Rubin J et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads\u2009+\u20095-fluorouracil), and high dose radiation\u2009+\u20095-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48(8):1705\u20131710","journal-title":"Cancer"},{"issue":"1","key":"4291_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","volume":"68","author":"L Huang","year":"2019","unstructured":"Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L et al (2019) Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 68(1):130\u2013139","journal-title":"Gut"},{"issue":"6","key":"4291_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA et al (2014) Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155(6):977\u2013988","journal-title":"Surgery"},{"issue":"Suppl 5","key":"4291_CR5","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Go\u00e9r\u00e9 D et al (2015) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals oncology: official J Eur Soc Med Oncol 26(Suppl 5):v56\u201368","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"4291_CR6","unstructured":"Network NCC Pancreatic Adenocarcinoma [01-03-2021]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"key":"4291_CR7","doi-asserted-by":"crossref","unstructured":"Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A et al (2020) Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med 9(4) :1129","DOI":"10.3390\/jcm9041129"},{"issue":"2","key":"4291_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/bjs5.46","volume":"2","author":"S Schorn","year":"2018","unstructured":"Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M et al (2018) Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open 2(2):52\u201361","journal-title":"BJS Open"},{"issue":"6","key":"4291_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/cam4.1071","volume":"6","author":"HX Zhan","year":"2017","unstructured":"Zhan HX, Xu JW, Wu D, Wu ZY, Wang L, Hu SY et al (2017) Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med 6(6):1201\u20131219","journal-title":"Cancer Med"},{"key":"4291_CR10","unstructured":"Castor EDC Castor Electronic Data Capture 2019 [27 Aug. 2019]. Available from: https:\/\/castoredc.com"},{"issue":"6","key":"4291_CR11","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1245\/s10434-019-08137-6","volume":"27","author":"S Lof","year":"2020","unstructured":"Lof S, Korrel M, van Hilst J, Alseidi A, Balzano G, Boggi U et al (2020) Impact of neoadjuvant therapy in resected pancreatic ductal adenocarcinoma of the pancreatic body or tail on surgical and oncological outcome: a propensity-score matched multicenter study. Ann Surg Oncol 27(6):1986\u20131996","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4291_CR12","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s11605-018-3725-x","volume":"22","author":"SL Zettervall","year":"2018","unstructured":"Zettervall SL, Ju T, Holzmacher JL, Rivas L, Lin PP, Vaziri K (2018) Neoadjuvant radiation is associated with fistula formation following pancreaticoduodenectomy. J Gastrointest Surg 22(6):1026\u20131033","journal-title":"J Gastrointest Surg"},{"issue":"12","key":"4291_CR13","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s11605-016-3286-9","volume":"20","author":"JW Denbo","year":"2016","unstructured":"Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M et al (2016) Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. J Gastrointest Surg 20(12):1975\u20131985","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"4291_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.surg.2011.03.001","volume":"150","author":"H Takahashi","year":"2011","unstructured":"Takahashi H, Ogawa H, Ohigashi H, Gotoh K, Yamada T, Ohue M et al (2011) Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery 150(3):547\u2013556","journal-title":"Surgery"},{"key":"4291_CR15","doi-asserted-by":"crossref","unstructured":"Vasavada B, Patel H Impact of neoadjuvant chemoradiotherapy on post-operative clinically significant pancreatic fistula \u2013 A systemic review and updated meta-analysis. medRxiv. 2020:2020.12.14.20248164.","DOI":"10.1101\/2020.12.14.20248164"},{"issue":"6","key":"4291_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/his.12234","volume":"63","author":"D Chatterjee","year":"2013","unstructured":"Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR et al (2013) Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology 63(6):841\u2013851","journal-title":"Histopathology"},{"key":"4291_CR17","doi-asserted-by":"publisher","unstructured":"Jang J-Y, Han Y, Lee H, Kim S-W, Kwon W, Lee K-H et al (2018) Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg 268(2):215\u2013222.\u00a0https:\/\/doi.org\/10.1097\/SLA.0000000000002705","DOI":"10.1097\/SLA.0000000000002705"},{"issue":"6","key":"4291_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","volume":"3","author":"M Reni","year":"2018","unstructured":"Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R et al (2018) Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial. Lancet Gastroenterol Hepatol 3(6):413\u2013423","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"16","key":"4291_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA et al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin oncology: official J Am Soc Clin Oncol 38(16):1763\u20131773","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"3","key":"4291_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A et al (2021) Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 7(3):421\u2013427","journal-title":"JAMA Oncol"},{"issue":"18suppl","key":"4291_CR21","doi-asserted-by":"publisher","first-page":"LBA4001","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4001","volume":"36","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Abdelghani MB, Chia-chi Wei A, Raoul JL et al (2018) Unicancer GI PRODIGE 24\/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol 36(18suppl):LBA4001\u2013LBA","journal-title":"J Clin Oncol"},{"issue":"1","key":"4291_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","volume":"21","author":"QP Janssen","year":"2021","unstructured":"Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene P et al (2021) Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 21(1):300","journal-title":"BMC Cancer"},{"issue":"5","key":"4291_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH et al (2018) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267(5):936\u2013945","journal-title":"Ann Surg"},{"issue":"6","key":"4291_CR24","first-page":"458","volume":"18","author":"SK Itchins","year":"2017","unstructured":"Itchins SK, Arena M, Nahm J, Pavlakis C, Clarke N (2017) Patterns and determinants of recurrence for pancreatic ductal adenocarcinoma after resection. JOP 18(6):458\u2013646","journal-title":"JOP"},{"issue":"8","key":"4291_CR25","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1245\/s10434-018-6558-7","volume":"25","author":"VP Groot","year":"2018","unstructured":"Groot VP, Gemenetzis G, Blair AB, Ding D, Javed AA, Burkhart RA et al (2018) Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg Oncol 25(8):2475\u20132483","journal-title":"Ann Surg Oncol"},{"key":"4291_CR26","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/j.pan.2020.07.289","volume":"20","author":"M Preuhs","year":"2020","unstructured":"Preuhs M, Samm N, Friess H, Demir I, Ceyhan G (2020) Patterns, timing, and predictive factors for local recurrence and distant metastasis in resected pancreatic ductal adenocarcinoma. Pancreatology 20:S151","journal-title":"Pancreatology"},{"key":"4291_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2019.11.002","volume":"125","author":"AEJ Latenstein","year":"2020","unstructured":"Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, de Hingh IHJT et al (2020) Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer 125:83\u201393","journal-title":"Eur J Cancer"},{"issue":"8","key":"4291_CR28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ejso.2020.02.016","volume":"46","author":"M Weniger","year":"2020","unstructured":"Weniger M, Miksch RC, Maisonneuve P, Werner J, D\u2019Haese JG (2020) Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades \u2013 A meta-regression. Eur J Surg Oncol 46(8):1516\u20131523","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"4291_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/SLA.0000000000005925","volume":"279","author":"T Sugawara","year":"2024","unstructured":"Sugawara T, Rodriguez Franco S, Sherman S, Torphy RJ, Colborn K, Franklin O et al (2024) Neoadjuvant chemotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: an updated nationwide study. Ann Surg 279(2):331\u2013339","journal-title":"Ann Surg"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-026-04291-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-026-04291-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-026-04291-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:02:12Z","timestamp":1790103732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-026-04291-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4291"],"URL":"https:\/\/doi.org\/10.1007\/s00423-026-04291-0","relation":{},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of Interest and Source of Funding: A.H. ; consultancy for Olympus through course in pancreatic surgery. The authors appreciate the support and funding from the Cancer Center Amsterdam Foundation, The Netherlands (CCA) to E.Z. ; the Lithuanian Gastroenterology Society, Lithuania to B.K.; Mylan; State Research Funding (VTR), Finland to R.A. and J.L.; the Sigrid Jus\u00e9lius Foundation, Finland to R.A. and J.L.; and the Italian Ministry of Health with Ricerca Corrente and 5\u2009\u00d7\u20091000 funds to P.M.; M.D.C. have been awarded an industry grant (Haemonetics, Inc) to conduct a multicentre study to evaluate the prognostic implications of TEG in cancer of the pancreas, and is a co-PI of a sponsored Boston Scientific study on the use of intra-operative pancreatoscopy in IPMN\u2019s patients. Funding had no involvement in the study design, data collection, data analysis, manuscript preparation, or publication decisions. For the remaining authors none were declared.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"246"}}